{
    "clinical_study": {
        "@rank": "94021", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Experimental", 
                "description": "Groups 1-4 multiple ascending doses of AZD7624 Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.\nCOPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 patients will receive matching placebo."
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Groups 1-4 multiple ascending doses of placebo Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.\nCOPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 will receive matching placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics\n      of multiple ascending doses of AZD7624 in healthy subjects and patients with chronic\n      obstructive pulmonary disease."
        }, 
        "brief_title": "To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "COPD", 
            "Healthy Subjects"
        ], 
        "condition_browse": {
            "mesh_term": "Pulmonary Disease, Chronic Obstructive"
        }, 
        "detailed_description": {
            "textblock": "A Phase I, Randomized, DoubleBlind Placebo-Controlled Study to Investigate the Safety,\n      Tolerability and Pharmacokinetics of Multiple Ascending Inhaled Doses (MAD) of AZD7624 to\n      Healthy Subjects and Patients with COPD"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects aged 18 to 55 years (inclusive) with suitable\n             veins for cannulation or repeated venipuncture.\n\n          -  Provision of signed and dated, written informed consent prior to any study specific\n             procedures\n\n          -  Plasma myoglobin and CK not above the upper reference range of the analysing\n             laboratory at Day -1\n\n          -  Male and/or female patients with COPD aged above18 years with suitable veins for\n             cannulation or repeated venipuncture.\n\n          -  Clinical diagnosis of COPD for more than 1 year at Visit 1, according to the Global\n             Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines\n\n        Exclusion Criteria:\n\n          -  Any clinically important illness, medical/surgical procedure or trauma within 4 weeks\n             of the first administration of the IP\n\n          -  Receipt of another new chemical entity (defined as a compound which has not been\n             approved for marketing) or participation in any other clinical study that included\n             drug treatment within at least 3 months of the first administration of the IP in this\n             study\n\n          -  Any clinically important abnormalities in clinical chemistry, haematology or\n             urinalysis results as judged by the Investigator\n\n          -  Any positive result on screening for serum hepatitis B surface antigen (HBsAg),\n             hepatitis C antibody and human immunodeficiency virus (HIV)\n\n          -  History or presence of gastrointestinal, hepatic or renal disease or any other\n             condition known to interfere with absorption, distribution, metabolism or excretion\n             of drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01817855", 
            "org_study_id": "D2550C00002"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "description": "Multiple ascending doses (starting from 300 \u00b5g lung deposited dose up to 1200 \u00b5g)  inhaled IMP via a nebulizer", 
                "intervention_name": "AZD7624", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2", 
                "description": "Multiple doses inhaled placebo via a nebulizer", 
                "intervention_name": "Placebo to match", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phase 1,", 
            "Safety,", 
            "Tolerability,", 
            "Healthy,", 
            "COPD patients"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom"
                }, 
                "name": "Research Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Randomized, DoubleBlind Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Inhaled Doses (MAD) of AZD7624 to Healthy Subjects and Patients With COPD", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Quintiles Drug Research Unit Call Centre", 
            "phone": "0800 634 1132"
        }, 
        "overall_official": [
            {
                "affiliation": "Quintiles Drg Research Centre At Guys Hosipital, 6 Newcomen Street London SE1 1YR", 
                "last_name": "Saeed Khan, MBBS, MRCP", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AstraZeneca, Wilmington, US", 
                "last_name": "Naimish Patel, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cohorts 1 and 4: Study duration [from screening visit (Day -42) through follow up visit (up to Day 22) at multiple timepoints up to 64 days] Cohorts 2 and 3: Study duration [from screening visit (Day -42) through follow up visit (up to Day 24) at multiple timepoints up to 66 days]", 
            "measure": "Change from baseline up to 66 days in safety variables (adverse events, vital signs, body temperature, physical exams, ECGs, telemetry, clinical laboratory safety tests and spirometry).", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 66 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01817855"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PK parameters: Cmax, tmax, \u03bbz; t1/2, area under the plasma concentration-time curve from zero to 24 hours [AUC(0-24)], from zero to the time of the last measurable concentration [AUC(0-last)] and from zero to infinity (AUC), CL/F and  Vz/F", 
                "measure": "AZD7624 single dose pharmacokinetics profile from blood in healthy volunteers (cohorts 1, 2 and 3) and COPD patients (cohort 4).", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and 8 (cohort 1), Day 1 and 9 (cohort 2 and 3), Day 1 and 7 (cohort 4): pre-dose, 5, 15 and 30 min, 1, 2, 3, 4, 6, 9, 12, 18 and 24 hrs (and 36, 48 and 72 hrs following dosing Day 1 for cohort 2 and 3)"
            }, 
            {
                "description": "PK parameters: Cmax, tmax, Cmin, area under the plasma concentration-time curve from zero to the end of the dosing interval [AUC(0-\u03c4)], CL/F, extent of accumulation on multiple dosing (RCmax and RAUC), and time dependency of the pharmacokinetics.", 
                "measure": "AZD7624 multiple dose pharmacokinetics profile from blood in healthy volunteers (cohorts 1, 2 and 3) and COPD patients (cohort 4).", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and 8 (cohort 1), Day 1 and 9 (cohort 2 and 3), Day 1 and 7 (cohort 4): pre-dose, 5, 15 and 30 min, 1, 2, 3, 4, 6, 9, 12, 18 and 24 hrs (and 36, 48 and 72 hrs following dosing Day 1 for cohort 2 and 3)"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}